中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (10): 760-764.doi: 10.12144/zgmfskin202510760

• 综述 • 上一篇    下一篇

儿童斑块型及泛发性脓疱型银屑病生物制剂治疗进展

李汶莉,杨欢   

  1. 重庆医科大学附属儿童医院皮肤科，国家儿童健康与疾病临床医学研究中心，儿童发育疾病研究教育部重点实验室，儿童代谢与炎症性疾病重庆市重点实验室，重庆，400015
  • 出版日期:2025-10-15 发布日期:2025-09-29

Biologic therapy for pediatric plaque psoriasis and generalized pustular psoriasis

LI Wenli, YANG Huan   

  1. Department of Dermatology Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400015, China
  • Online:2025-10-15 Published:2025-09-29

PDF (PC)

21

摘要： 银屑病的病理生理机制涉及多基因遗传背景及免疫调控网络失衡，Th17细胞介导的IL-23/IL-17炎症轴激活被认为是斑块型银屑病的关键驱动因素，IL-36通路异常与泛发性脓疱型银屑病的急性发作密切，与之相关的生物制剂已成为治疗银屑病的重要选择。本文对生物制剂治疗儿童斑块型及泛发性脓疱型银屑病的治疗进展进行综述。

关键词: 生物制剂, 斑块型银屑病, 泛发性脓疱型银屑病, 儿童

Abstract: The pathophysiological mechanism of psoriasis involves a polygenic genetic background and an imbalance in the immune regulatory network. The activation of the IL-23/IL-17 inflammatory axis mediated by Th17 cells is considered a key driver of plaque psoriasis. Abnormalities in the IL-36 pathway are closely associated with acute exacerbations of generalized pustular psoriasis. Biological agents related to these pathways have become important options for the treatment of psoriasis. This paper reviews the progress in the treatment of childhood plaque psoriasis and generalized pustular psoriasis with biological agents.

Key words: biologics, plaque psoriasis, generalized pustular psoriasis, children